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ABSTRACT
Treatment of metastatic renal cell carcinoma (mRCC) with agents that block 
signaling through vascular endothelial growth factor receptor 2 (VEGFR2) induces 
disease regression or stabilization in some patients; however, these responses tend 
to be short-lived. Therefore, development of combination therapies that can extend 
the efficacy of VEGFR antagonists in mRCC remains a priority.
We studied murine xenograft models of RCC that become refractory to treatment 
with the VEGFR tyrosine kinase inhibitor (TKI) sunitinib. Dalantercept is a novel 
antagonist of Activin receptor-like kinase 1 (ALK1)/Bone morphogenetic protein 
(BMP) 9 signaling. Dalantercept inhibited growth in the murine A498 xenograft 
model which correlated with hyperdilation of the tumor vasculature and an increase 
in tumor hypoxia. When combined with sunitinib, dalantercept induced tumor 
necrosis and prevented tumor regrowth and revascularization typically seen with 
sunitinib monotherapy in two RCC models. Combination therapy led to significant 
downregulation of angiogenic genes as well as downregulation of endothelial specific 
gene expression particularly of the Notch signaling pathway.
We demonstrate that simultaneous targeting of molecules that control distinct 
phases of angiogenesis, such as ALK1 and VEGFR, is a valid strategy for treatment of 
mRCC. At the molecular level, combination therapy leads to downregulation of Notch 
signaling.
INTRODUCTION
An increased understanding of the molecular biology 
of RCC has led to the identification of angiogenesis as a key 
contributor to its pathogenesis. Alterations in the Von Hippel 
Lindau (VHL) gene, hypoxia-inducible factor 1- alpha 
(HIF1-α) accumulation and vascular endothelial growth 
factor (VEGF) overexpression have been documented 
in the majority of clear cell RCC. Multiple antagonists 
of the VEGF signaling pathway such as the multikinase 
inhibitors sunitinib, pazopanib, axitinib and sorafenib and 
the monoclonal antibody to VEGFA, bevacizumab, are 
approved for treatment of patients with advanced RCC 
[1–4]. While each of these anti-VEGF strategies has shown 
clinical benefit in the majority of patients, many patients 
are either resistant to such therapy or more commonly 
acquire resistance to these drugs within a year of treatment 
initiation. Therefore, targeting additional angiogenic 
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signaling pathways may represent a promising therapeutic 
approach for patients with advanced RCC.
We have previously shown in a mouse model of 
RCC that resistance to VEGFR inhibitors is accompanied 
by reestablishment of tumor vasculature [5]. Tumors 
treated with sunitinib showed a brief period of tumor 
stabilization and decreased blood flow as measured by 
arterial spin labeled magnetic resonance imaging (ASL 
MRI) [5]. Subsequently, despite continued sunitinib 
administration, tumors showed a resumption of blood flow 
(albeit to a lesser extent than vehicle treated tumors) and 
tumor growth. We have shown by IHC and ASL MRI, that 
the development of sunitinib-resistant vessels is inhibited 
by supplemental activation of endogenous angiostatic 
pathways such as CXCL9 [5]. Based on these findings, 
we hypothesize that optimal antiangiogenic regimens will 
include combinations of agents targeting different steps in 
tumor angiogenesis.
Given the complexity of the neoangiogenic 
process, it is likely that simultaneous inhibition of 
multiple regulatory pathways including VEGF will 
increase the magnitude and duration of antitumor 
effects in RCC. Members of the TGF-beta superfamily 
have been implicated as important regulators of 
angiogenesis during embryonic development [6-8]. 
ALK1 and endoglin (ENG) are receptors in the TGF-
beta superfamily of signaling molecules known to be 
expressed on actively forming arterial endothelial cells 
[9,10]. The superfamily ligands bone morphogenetic 
protein (BMP) 9 and 10 bind with high affinity to a 
heteromeric complex consisting of ALK1, a cognate 
superfamily type II receptor, and ENG, an accessory 
receptor, to induce specific serine/threonine kinase 
activity and phosphorylation of regulatory proteins 
(SMAD 1/5/8) which translocate to the nucleus and 
activate transcription of target genes [6,9,11-13].
Evidence for ALK1 participation in vascular 
formation came from the discovery that mutations in 
the human ACVRL1 gene (encodes ALK1 protein) 
are the cause of hereditary hemorrhagic telangiectasia 
(HHT) type 2 [14]. Mutations in the human endoglin 
(ENG, CD105) gene were found to be responsible for 
HHT type 1, thus indicating the importance of this 
signaling pathway in vascular formation. [15]. Patients 
with HHT exhibit abnormal vessel development, 
including arteriovenous malformations (AVMs) in which 
intervening capillary beds are absent. Genetic knockout 
of either the ACVRL1 or ENG genes in mice leads to 
embryonic lethality due to defective angiogenesis. 
Heterozygous mice carrying a single allele of ACVR1 
or ENG develop HHT-like symptoms including the 
development of telangiectasias [16,17]. Whereas VEGF 
is known to play a key role in initiation of angiogenesis, 
ALK1 pathway has been shown to regulate the 
maturation phase of angiogenesis [18].
Dalantercept is a fully-human, recombinant fusion 
protein produced by linking the extracellular domain of 
the human ALK1 receptor to the Fc portion of human 
immunoglobulin G1 (ALK1-Fc) [12]. Dalantercept 
functions as a selective trap for BMP9/BMP10, and we 
and others have shown that blocking ALK1 signaling with 
ALK1-Fc results in defective development of vascular 
and lymphatic networks in vivo [6,7,12]. Treatment with 
ALK1-Fc suppressed tumor progression and decreased 
tumor vasculature in a RIP1-Tag2 transgenic model of 
pancreatic islet cell cancer [19]. Interestingly, similar to 
ALK1-Fc protein, soluble endoglin-Fc was found to bind 
selectively to BMP9/BMP10 and to effectively inhibit both 
angiogenesis and tumor xenograft growth in vivo [11].
In the present study we show that combined 
inhibition of ALK1 and VEGFR pathways has profound 
effects on tumor angiogenesis. The mechanism of action 
of the combination treatment is likely in part due to 
dysregulation of interconnected VEGF/VEGFR, BMP/
ALK1 and Dll4/Notch signaling pathways, which 
interferes with the development of acquired resistance to 
VEGFR TKI. Thus, combined antagonism of the ALK1 
and VEGFR pathways is a promising novel therapeutic 
option for patients with advanced RCC.
RESULTS
Treatment with dalantercept alters tumor 
vascular network, increases tumor hypoxia and 
delays tumor growth
Treatment with dalantercept delayed growth of 
A498 human RCC xenograft tumors in a dose-dependent 
manner with both 10 mg/kg and 30 mg/kg doses showing 
statistically significant effects on the tumor growth while 
3mg/kg showed only a modest effect (Figure 1A). Based 
on these data, the 10 mg/kg dose of dalantercept was 
chosen for combination studies with the VEGFR TKI 
sunitinib (Figure 1A).
To view the in vivo treatment-induced changes in the 
tumor vascular network, we perfused dalantercept-treated 
and control mice with the Microfil imaging reagent. Three-
dimensional reconstruction of the tumor vascular network 
revealed profound aberrations in the network organization 
in dalantercept-treated tumors (Figure 1B). Large, dilated 
blood vessels were prominent in the dalantercept-treated 
tumors while the typical tree-like branching pattern was 
missing. Average vessel radius increased from 30 μm 
in the control tumors to ~60 μm in dalantercept treated 
tumors, which correlated with an overall shift in the 
distribution of vessel size toward larger vessels (Figure 
1B). The frequency of Microfil-perfused small blood 
vessels (<50 um radius) was dramatically reduced in 
dalantercept treated tumors (22% vs 74% in control 
group), whereas the frequency of large vessels (>50 um or 
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>100 um radius) was correspondingly increased (Figure 
1B, 1C).
This phenomenon resembles vascular remodeling 
and vessel dilation occurring upon formation of 
arteriovenous malformations (AVMs) in ALK1-
deficient blood vessels in a mouse model of HHT 
[20]. Development of such AVMs in HHT leads to 
abnormal high-velocity, turbulent arterial blood flow 
and an elevation of oxygen saturation levels in the 
venous vessels. Thus we reasoned that it was likely that 
AVM formation was also taking place in A498 tumors 
treated with dalantercept. Tumor vascular networks 
compromised by the AVMs would be less efficient in 
the delivery of oxygen and nutrients to tumor cells. To 
test this hypothesis we quantified hypoxic areas in the 
tumor tissues using the hypoxia probe, EF5 [21]. In line 
with this hypothesis, immunohistochemical analysis of 
EF5-positive areas in A498 tumors treated with either 
vehicle or dalantercept for 2 weeks revealed more 
extensive tumor hypoxia in dalantercept treated tumors 
(P<0.033) (Figure 1D).
Dalantercept combined with sunitinib shows 
durable tumor stasis by preventing resumption 
of tumor blood flow in human RCC xenograft 
models
Next we wanted to explore if combination treatment 
of dalantercept and a VEGFR antagonist, TKI sunitinib, 
could provide any additional benefit over sunitinib therapy 
alone. Treatment with either sunitinib (Su) or dalantercept 
(Dal) alone slowed A498 tumor growth (Figure 2A), 
(comparison of tumor volumes on day 22, vehicle 2310.3 
± 251.9 mm3 vs Su 1308.3 ± 88.1 mm3; P=0.013; and 
vehicle vs Dal 1290.1 ± 16.7mm3; P=0.009). Combination 
of the two agents led to profound tumor growth inhibition 
for up to 7 weeks with continuous dosing (Figure 2A), 
(Su + Dal 944.4 ± 75.4mm3 vs Su 2068.8 ± 184.4mm3; 
P=0.003). This combination regimen was also tested in 
the 786-O RCC xenograft model. While dalantercept 
monotherapy was not able to inhibit tumor growth in 
the 786-O model, the combination of dalantercept and 
sunitinib led to greater suppression of tumor growth as 
Figure 1: Dalantercept slows RCC tumor growth and affects tumor vasculature in vivo. A. Growth curves depicting tumor 
volume of A498 derived RCC xenografts treated with vehicle, dalantercept (3mg/kg), dalantercept (10mg/kg) and dalantercept (30mg/
kg). B. Representative images of tumor vascular networks after treatment with either vehicle or dalantercept (10 mg/kg, i.p., tiw) for 3 
weeks. Perfusion with Microfil, acquisition and analysis of uCT images is described in Materials and methods. C. Normalized frequency 
distribution of blood vessel radius calculated from the 3D vascular network models (data from individual tumors, n=3 per group). Blood 
vessels were binned into three groups according to the vessel radius (<50um, 50-100 um and >100 um) and the frequency of vessels in 
each group was calculated, P<0.05. D. Quantification of hypoxic areas in tumor tissue using hypoxic probe EF5 and immunohistochemistry 
shows more tumor hypoxia in dalantercept treated tumors as compared to the vehicle treated tumors (*P<0.033).
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compared with sunitinib monotherapy alone and resulted 
in durable tumor stasis (Figure 2B), (tumor volume, ~day 
34 Su + Dal 548.7 ± 35.5 mm3 vs Su 831.0 ± 53.7mm3; 
P=0.0007; and ~Day 48 Su + Dal 596.9 ± 40.5 mm3 vs Su 
1039.1 ± 63.0 mm3; P=0.0001).
Previously, in both A498 and 786-O models, 
treatment with sunitinib led to a significant reduction 
in tumor blood flow as early as 3 days after treatment 
initiation, followed by partial restoration of tumor blood 
flow after several weeks of chronic dosing [5]. We 
performed serial ASL MRI imaging to monitor changes 
in tumor blood flow in relation to the drug treatment in 
both tumor models. As expected, we observed resumption 
of tumor blood flow in the A498 model after longterm 
treatment with sunitinib (Supplementary Figure S1A). In 
contrast, combination treatment with dalantercept plus 
sunitinib in A498 tumor-bearing mice showed reduced 
blood flow compared with sunitinib alone evident on 
day 50 after treatment initiation (Figure 2C), (Su 64.9 
± 4.2ml/100g/min vs Su + Dal 37.6 ± 7.5ml/100g/min; 
P=0.02). A similar effect of the combination treatment on 
tumor blood flow was observed in the 786-O xenograft 
model (Figure 2D). On day 48, residual tumor blood flow 
was significantly reduced in the combined-treatment 
cohort (12.3 ± 1.7ml/100g/min) compared to the 
sunitinib-only group (37.1 ± 15.6ml/100g/min; P=0.02). 
Consistent with the Microfil results and the known role 
of ALK1 on the vasculature, dalantercept monotherapy 
led to an increase in tumor blood flow (Supplementary 
Figure S1B).
To further assess the effect of dalantercept and 
sunitinib on tumors, we compared tumor necrosis and 
microvessel density (MVD) in the treatment arms in 
the A498 tumor model. At the time of the ASL MRI 
(day 48-50), viable tumor and necrosis were quantified. 
The combination of sunitinib and dalantercept yielded a 
higher ratio of necrosis/viable tumor than either treatment 
alone (Figure 3A, 3B), (Su + Dal vs Vehicle: P=0.0005; 
Su + Dal vs Dal: P=0.07; Su + Dal vs Su: P=0.01; Su vs 
Vehicle: P=0.01; Dal vs Vehicle: P=0.04).
We also performed IHC to assess for the effects of 
combination treatment on tumor vasculature (Figure 3C). 
Tumors treated with sunitinib showed a decrease in MVD. 
Combination therapy decreased MVD to a greater extent 
Figure 2: Combination of dalantercept with sunitinib leads to durable tumor growth inhibition in RCC xenograft 
models. A498 tumor-bearing mice A. or 786-0 tumor-bearing mice B. were randomized into four groups and treated with vehicle and 10 
mg/kg control Fc protein (black line); vehicle and 10 mg/kg dalantercept (brown line); 40 mg/kg sunitinib and 10 mg/kg control Fc (green 
line); or combination of 40 mg/kg sunitinib and 10 mg/kg dalantercept (blue line). Plotted are average tumor volumes +/− SE. Tumor 
blood flow was measured by ASL MRI in A498 xenograft bearing animals on the day of sacrifice (roughly day 50 of drug treatment). 
Representative images of A498 C. or 786-O D. tumors treated with either sunitinib + control Fc or sunitinib + dalantercept are shown. 
Calculated tumor blood flow was color coded according to the scale from 0 to 160 ml/100g/min. Day 50 tumor blood flow averages (+/−SE) 
from animals treated with sunitinib + control Fc protein versus combination of sunitinib + dalantercept, *P<0.05.
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than individual therapies (Figure 3C, 3D). However, the 
comparison of sunitinib vs combination did not reach 
statistical significance (P=0.05) likely due to the fact that 
the amount of viable tumor remaining for MVD analysis 
was extremely small in the combination treatment group 
and sunitinib treated tumors had low MVD.
Combination of dalantercept and sunitinib 
suppresses growth of A498 tumors that 
progressed on sunitinib monotherapy
We then explored the efficacy of combination 
therapy in the context of sunitinib-refractory RCC. 
Animals with established A498 tumors were treated with 
sunitinib until tumor diameter increased by 2 mm (the 
smallest measurable size increase). At that point, treatment 
was stopped for 2 days and mice were randomized into 
three groups: one group continued to receive sunitinib, the 
second group was switched to dalantercept treatment and 
the third group received both sunitinib and dalantercept. 
The combination treatment showed a significant delay of 
tumor growth compared to either dalantercept alone or 
continued sunitinib alone (Figure 4A), (normalized tumor 
volumes on day 40 post treatment switch, Su switched 
to Dal: 3.6 ± 0.4 vs Su switched to Su + Dal: 1.3 ± 0.1; 
P=0.008; Su continued: 2.8 ± 0.2 vs Su switched to Su 
+ Dal: 1.3 ± 0.1; P=0.007). This delay in tumor growth 
was associated with a further decrease in tumor blood 
flow after combination treatment vs continued sunitinib 
treatment (Su switched to Su + Dal: 23.7 ± 9.8ml/100g/
min vs Su continued: 43.3 ± 15.8ml/100g/min; P=0.046). 
The switch to dalantercept from sunitinib treatment led 
to increased tumor blood flow compared to continuous 
sunitinib treatment (Su switched to Dal: 117.9 ± 
41.4ml/100g/min vs Su continued: 43.3 ± 15.8ml/100g/
min; P=0.006), as evaluated by ASL MRI on day 40 post 
switch (Figure 4B).
Unsupervised analysis of RNA sequencing data 
shows differential gene expression after ALK1 
and VEGFR inhibition
To understand the mechanism underlying 
combination therapy, RNA sequencing of treated tumors 
Figure 3: Combination of sunitinib and dalantercept induces tumor necrosis and loss of tumor vasculature. A. A498 
tumors treated with vehicle, Vehicle + dalantercept, sunitinib + control Fc or sunitinib + dalantercept, were stained with hematoxylin and 
eosin and areas of necrosis and viable tumor were outlined (shown at 5x magnification). B. Quantitation of viable tumor/necrosis was 
performed. (Vehicle vs Su P=0.058; Vehicle vs Dal P=0.04; Vehicle vs Su + Dal P=0.0007; Su vs Su + Dal P=0.038; Dal vs Su + Dal P=0.09. 
C. Immunohistochemistry of CD34 expression in tumors treated with vehicle, sunitinib, and sunitinib plus dalantercept combination. D. 
Quantification of area enclosed by CD 34 positive stain representative of blood vessel area (Vehicle vs Su P=0.005; Vehicle vs Su + Dal 
P=0.0001; Su vs Dal P=0.03; Su vs Su + Dal P=0.05; Dal vs Su + Dal P=0.0005)
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was performed. Mice harboring A498 tumors were treated 
with vehicle, sunitinib, dalantercept or combination 
(sunitinib + dalantercept) and tumors were harvested for 
RNA sequencing at 30 days or when tumors reached 20mm 
in long axis. High quality RNA sequencing data was aligned 
against mouse and human genomes to understand the effects 
of various treatments on host and tumor transcriptomes.
The sequencing reads achieved on average ~79.9% 
and ~15.2% alignments against tumor and host genomes, 
respectively. The low alignment against the mouse 
genome was expected as sequencing was performed on 
human xenograft tumors and majority of the specimen 
consisted of human tumor cells with a smaller amount of 
mouse stromal tissue. The alignments against the mouse 
genome could represent this host stromal tissue or merely 
cross-reactivity between mouse and human genomes. 
For secondary validation of the gene expression changes, 
we performed qRT-PCR on multiple host significantly 
differentially expressed genes (Supplementary Figure S2). 
A significant correlation was observed between RNA-Seq 
and qRT-PCR based gene expression.
The unsupervised analysis using PCA demonstrated 
a good separation between untreated and treated 
samples along primary component (PC) 1. PCA showed 
that samples treated with combination (sunitinib + 
dalantercept) and monotherapy (sunitinib or dalantercept) 
formed separate groups indicating differential 
transcriptome changes (Supplementary Figure S3).
We then focused on the “host” genes, which were 
downregulated by either dalantercept, sunitinib or the 
combination and compared those to a previously reported 
angiogenic/Endothelial Cell meta-signature developed 
using several human cancers including RCC [22]. As 
shown in Figure 5A, of the 471 upregulated genes from 
the angiogenesis meta-signature, 92 (~20%) genes were 
significantly downregulated (Absolute Fold Change ≥2 
and FDR P value <0.05) in the combination treatment 
group. Of the 92 genes, 23 genes were commonly 
downregulated by both sunitinib monotherapy as well 
as combination therapy (Figure 5A, Panel I), and 65 
genes were significantly affected by the combination 
treatment only but not by monotherapy (Figure 5A, Panel 
II). Nine out of the top 20 genes in the angiogenesis 
meta-signature were significantly downregulated by the 
combination treatment but not by sunitinib or dalantercept 
monotherapy, (Figure 5A, Panel II, blue highlighted) 
suggesting that combination of sunitinib and dalantercept 
has a more profound effect on tumor angiogenesis than 
either agent alone.
Combination therapy leads to downregulation of 
the Notch pathway
To identify the key pathways and regulators 
affected by the combination treatment we performed a 
systems biology oriented analysis of the gene expression 
changes. Interestingly, Notch signaling emerged as one 
of the top pathways downregulated specifically in the 
combination treatment group. The Notch/DLL4 pathway 
limits vascular sprouting during angiogenesis leading to 
maturation of the vascular bed. The analysis identified 
Notch 1 as a central node of the interactive map with 
multiple members of the Notch family (i.e. Notch1, Notch 
3, Notch 4) significantly downregulated by combination 
treatment (Figure 5B). Expression of Notch pathway 
signal transducing molecules, such as Hey1/2 and HES1 
was also affected. The Notch ligand DLL4 and the 
endothelial tip cell marker ESM1 were affected both by 
sunitinib monotherapy as well as combination treatment 
but more profoundly by the latter. Using qRT-PCR, we 
Figure 4: Combination of dalantercept with sunitinib slows tumor growth and further reduces tumor blood flow in 
sunitinib resistant tumors. A. A498 tumor-bearing mice were treated with sunitinib (40 mg/kg) until the tumors showed a 2 mm 
increase in long axis. After a 2 day drug holiday, animals were given vehicle (black line), sunitinib at (40 mg/kg, green line), dalantercept 
(10 mg/kg, brown line) or the combination of both drugs (blue line). Average tumor volume normalized to the initial average tumor volume 
for each group is shown. B. tumor perfusion was evaluated by ASL MRI on day 40 after the treatment change and average tumor perfusion 
is plotted in the graph. Su switched to the combination of Su + Dal vs Su continuous; * P=0.047. Su switched to Dal vs Su continuous; § 
P=0.006.
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further validated significant downregulation of some of 
these key genes (ESM1, DLL4, HEY1) after combination 
therapy (Figure 5C).
Reduced expression of genes involved in tumor 
angiogenesis may reflect general loss of endothelial cells 
due to the drug treatment. To take this into account, we 
normalized the expression of angiogenic genes from 
our murine gene expression dataset to the expression of 
an endothelial cell specific gene, Von Willebrand factor 
(VWF). Normalized expression of multiple members 
of the Notch signaling pathway was still significantly 
downregulated in the combination group in contrast to 
sunitinib or dalantercept monotherapy groups (Figure 5D).
BMP9 is expressed in human RCC
Previously, ALK1 expression was detected by IHC 
in the vasculature of most human tumors, including clear 
cell RCC [23]. Here we assessed BMP9 expression in 
cases of primary clear cell RCC to assess expression of 
Figure 5: Comparative analysis of tumor angiogenesis signature and RCC xenograft host transcriptome alterations 
due to sunitinib, dalantercept and combination therapies. A. Comparative analysis of tumor angiogenesis upregulated genes 
(Green Circle) with genes that are significantly downregulated with sunitinib (Red Circle), dalantercept (Yellow Circle) and combination 
therapy (Blue Circle). Combination therapy significantly downregulated ~20% of the upregulated genes (i.e. 92 genes) from the primary 
tumor angiogenesis signature. Panel I depicts fold change based heatmap of 23 angiogenesis related genes that are downregulated both due 
to sunitinib and combination therapy. Panel II shows the heatmap of 65 angiogenesis related genes that are only significantly downregulated 
by combination therapy but not by monotherapy. The panel consists of 9 out of top 20 angiogenesis related genes (shown in Blue) as 
identified by Masiero et al [22]. B. Key regulatory molecules associated with combination treatment. Heatmap depicts key regulatory genes 
that are specifically inhibited or activated by combinationtreatment. Magnitude of activation and inhibition is calculated on the basis of 
Z-score and shown using pseudocolor scale (−3 to 3) with red color denoting activated and green color denoting inhibited key regulators. 
An interactive network of combo effected key regulator and target genes are also shown. The intensity of node color indicates the degree of 
up-regulation (red) and down-regulation (green) by combination treatment compared to untreated samples. C. Validation of Notch signaling 
target genes altered by combination treatment. RT-PCR was performed on vehicle, sunitinib, dalantercept and combination treated tumors in 
triplicate with at least two tumors per arm (n=2-3 tumors per arm). Graph shows mean ± SEM of relative mRNA levels after normalization 
to 18S copies. *, P< 0.05, **, P<0.01. D. Combination therapy significantly (P<0.01) downregulated expression of more than 2 dozen 
endothelial specific genes. The analysis was performed after normalizing the transcript expression to the expression of VWF, an endothelial 
specific gene. Shown is the heatmap of endothelial genes significantly downregulated by combination therapy. The columns represent 
samples and the rows represent genes. Gene expression is shown with a pseudocolor scale (−3 to 3) with red color denoting increase and 
green color denoting decrease in gene expression. The significance of downregulation of endothelial genes in different comparisons is 
shown by asterisk (** P<0.001, * P<0.05).
Oncotarget41864www.impactjournals.com/oncotarget
the ALK1 ligand in human tumor cells (Figure 6). Positive 
cytoplasmic BMP9 expression in tumor cells was observed 
in 10 out of 12 (83%) primary clear cell RCC nephrectomy 
specimens. In one case, the corresponding lung metastasis 
was also available and BMP9 was observed to be expressed 
in both the primary tumor and in the metastasis.
DISCUSSION
Angiogenesis involves a balance of multiple 
pathways exerting effects on distinct coordinated steps. The 
ALK1 signaling pathway plays a major role in regulation 
of normal vasculogenesis. ALK1 and its co-receptor ENG 
are co-expressed on the surface of endothelial cells during 
active angiogenesis, and a mutation in either one results in 
hereditary hemorrhagic telangiectasia (HHT), an autosomal 
dominant vascular dysplasia syndrome [24,25]. BMP9 and 
BMP10 are circulating ligands which induce activation of 
the receptor complex and are thought to play a key role 
in the maturational phase of the vascular and lymphatic 
network during embryonic development [6,7,18,26]. We 
have previously reported that both ALK1-Fc and ENG-Fc 
fusion proteins selectively bind BMP9 and BMP10 and 
display single agent anti-angiogenic and anti-tumor effects 
in mouse models [11,12,19].
Here we used xenograft models of RCC to show that 
treatment with dalantercept led to profound changes in the 
tumor vascular network typified by significant reduction 
in frequency of small blood vessels and an increase in 
large, dilated vessels (Figure 1B, 1C). The observed 
changes in the tumor vascular network are consistent 
with the known phenotype of HHT vessels and with 
previous results in a mouse model of conditional ALK1 
inactivation, in which abnormal arterio-venous junctions 
appear, leading to shunting of local blood circulation and 
hyperdilation of veins [17]. However, the blood flow of 
small vessels and effective delivery of oxygen to tumor 
cells was significantly decreased under such conditions as 
revealed by increase in hypoxic areas in the tumors from 
dalantercept-treated animals (Figure 1D).
This is the first study to demonstrate that combination 
of the VEGFR inhibitor sunitinib with dalantercept leads to 
prolonged tumor stasis in human RCC xenograft models. 
Moreover, the combination of dalantercept and sunitinib 
was also effective in inhibiting growth of A498 tumors that 
became refractory to sunitinib monotherapy. The tumor 
growth inhibition effect of the combination treatment 
correlated with further decrease in tumor vasculature, tumor 
perfusion and an increase in tumor necrosis at the end of 
treatment, compared to sunitinib monotherapy. These data 
have led to clinical testing of the combination of a VEGFR 
TKI (axitinib) and dalantercept.
Our analysis of the murine transcriptome of treated 
A498 xenografts revealed a significant overlap between 
genes downregulated by either sunitinib monotherapy or 
the combination treatment and the previously published 
angiogenic meta-signature (Figure 5A) [22]. Among the 
most significantly affected genes, we found several members 
Figure 6: BMP9 is expressed in human RCC. Representative images of FFPE samples immunostained with anti-BMP9 antibody 
are shown. A. Positive and B. Negative CHO cell line controls were used for antibody optimization. C. Positive primary clear cell RCC. 
Note the presence of positive tumor cells both in Fuhrman nuclear grade 2 area (arrow) and in Fuhrman nuclear grade 2 area, D. Negative 
primary ccRCC, E. Positive primary ccRCC and F. Corresponding positive lung metastasis.
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of the Notch family as well Notch signal transducing 
molecules (Figure 5B). By normalizing gene expression 
to the endothelial specific gene, VWF, we showed that 
reduced expression of multiple members of Notch pathway 
was not simply due to loss of endothelial cells in the treated 
tumors. It appears that one of the potential mechanisms by 
which combined VEGFR and ALK1 inhibition may delay 
angiogenic escape in RCC is through downregulation of 
the Notch signaling pathway (Figure 5D). ALK1 and Notch 
pathways have recently been shown to work synergistically 
in stalk endothelial cells to repress tip cell formation and 
sprouting [27]. Moreover, DLL4 blockade has been shown 
to improve the anti-tumor effects of VEGF inhibition in 
xenograft models [28]. We hypothesize that hypersprouting 
and the disorganized, immature vascular network induced 
by ALK1/Notch inhibition is primed for optimal destruction 
in response to VEGF pathway inhibition.
Due to technical reasons, we were unable to detect 
BMP9 expression in murine tumors, however we did detect 
expression in human RCC specimens. It is intriguing that 
our analysis of a small number of tumor samples from 
primary RCC showed the majority (10 out 12) of the tumors 
expressing BMP9 at moderate to high levels. It remains to 
be determined if tumor BMP9 expression correlates with 
responses to dalantercept in the clinic.
Several ALK1 pathway antagonists are under current 
investigation in clinical trials. Dalantercept and antibodies 
directed against ALK1 (Pfizer, PF-03446962) and ENG 
(Tracon, TRC105) have all shown antitumor activity in 
the setting of VEGF pathway inhibition [23,29-31]. While 
these findings are consistent with those presented here, 
each approach to ALK1 pathway inhibition is likely to 
have distinct effects in the clinical setting, and particularly 
when combined with different VEGF pathway inhibitors.
Preclinical studies of melanoma and breast cancer 
have shown that the anti-ALK1 monoclonal antibody 
(PF-03446962) as monotherapy did not show any 
significant anti-tumor efficacy but it did enhance tumor 
growth inhibition of a VEGFR TKI or bevacizumab [23]. 
The combination treatment was reported to diminish 
endothelial cell/pericyte co-staining in the xenograft tumors, 
however, the mechanism of the combination effect was not 
fully elucidated. Since ALK1 is expressed by activated 
endothelial cells, a direct antibody-mediated cytotoxicity 
towards ALK1 positive endothelial cells when combined 
with VEGF pathway inhibition could not be ruled out. Here 
we used a different strategy to block this pathway, BMP9/10 
ligand trap, to show that simultaneous antagonism of ALK1 
and VEGFR pathways resulted in downregulation of the 
Notch pathway. This leads to further decrease in tumor 
blood flow and durable growth inhibition in both sunitinib-
naïve and sunitinib-refractory tumors. The combined 
dysregulation of VEGF/VEGFR, BMP9/ALK1 and Dll4/
Notch signaling pathways can lead to a more profound 
effects on tumor angiogenesis delaying the development of 
acquired resistance to VEGFR TKI in RCC.
In a completed phase 1 study, dalantercept showed 
anti-tumor activity in patients with advanced cancer and 
a safety profile relatively distinct from inhibitors of the 
VEGF pathway [32]. Our data support the hypothesis 
that the combination of dalantercept and a VEGFR TKI 
can control growth of TKI-resistant RCC tumors. We 
anticipate similar results with the combination of axitinib 
with dalantercept due to the common mechanism of action 
between axitinib and sunitinib. Based on these findings, 
a multicenter randomized phase II study is currently 
underway exploring the combination of dalantercept plus 
axitinib vs axitinib plus placebo in patients with advanced 
RCC refractory to anti-VEGF therapy.
MATERIALS AND METHODS
Drug formulation and administration
Dalantercept (ALK1-Fc), and the control murine 
Fc protein were manufactured at Acceleron Pharma, 
Inc. and described elsewhere [11,12]. The recombinant 
proteins were diluted in TBS or PBS to 2 mg/ml and dosed 
intraperitoneally at 5 ml/kg three times a week. Sunitinib 
malate (clinical grade) was resuspended in citrate buffer 
(pH 2.3) and dosed at 40 mg/kg given by oral gavage 
daily, 6/7 days per week.
Cell culture
The human VHL deficient human RCC cell lines, 
786-O and A498 were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA) and cultured 
for less than one month in aliquots and then frozen. 
Freshly thawed aliquots were used for each experiment. 
A498 cells were grown in Eagle’s Minimum Essential 
Medium (EMEM). 786-O cells were cultured in RPMI 
1640 medium (Cellgro).
Tumor xenograft studies
For subcutaneous xenograft tumor models, female 
athymic nude/beige mice (Charles River Laboratories) or 
athymic nude mice (Harlan Laboratories) were used. The 
mice were housed and maintained in laminar flow cabinets 
under specific pathogen-free conditions. All experiments 
were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Beth Israel Deaconess Medical 
Center or the local IACUC at Acceleron Pharma, Inc.
To establish RCC tumor xenografts, 786-O and 
A498 tumor cells were injected subcutaneously (107 cells) 
into the flanks of 6–8 week old mice (~20 g on average). 
When tumors reached 12 mm along the long axis (~500 
mm3 in volume), mice were randomized into treatment 
groups (5–8 mice per group). Treatment was continued 
until tumors reached 20 mm along the long axis or until 
50 days after treatment initiation.
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Tumor blood flow imaging
Tumor blood flow imaging with arterial spin-labeled 
MRI (ASL MRI) was performed as previously described 
[5,33,34]. Briefly, mice were anesthetized and imaged 
with a 3-cm surface coil on a 3.0 T whole-body clinical 
MRI scanner. A single transverse slice of ASL imaging 
was carefully positioned at the center of the tumor, which 
was marked on the skin with a permanent marker pen 
for follow-up MRI studies. ASL images were obtained 
with a single-shot fast spin echo sequence by using a 
background suppressed and flow-sensitive alternating 
inversion-recovery strategy. Using standard methods to 
quantify tumor blood flow [35], a region of interest was 
drawn around the peripheral margin of the tumor on the 
reference image that was then copied to the blood flow 
image. The mean blood flow for the tumor tissue within 
the region of interest was derived.
3D tumor vascular network imaging and analysis
Micro-computed tomography (µCT) vascular 
imaging was used to compare tumor vascular networks 
between drug-treated and control groups. Animals 
were anesthetized with isoflurane and perfused with a 
solution of heparinized-saline (1000 unit/ml) followed 
by perfusion with Microfil (Flow Tech Inc., Carver, 
MA, USA), a polymerizing silicone rubber contrast 
agent. Perfused animals were sacrificed and kept at 4oC 
overnight to allow polymerization. The following day 
tumors were resected and fixed in 10% formalin and sent 
to SCANCO Medical for µCT imaging and subsequent 
image analysis. All samples were scanned on a high-
resolution, volumetric µCT scanner (µCT40, SCANCO 
Medical, Zurich, Switzerland) using the following 
parameters: 10 µm isotropic voxel resolution, 300 ms 
exposure time, 2000 views, and 3 frames per view. The 
µCT-generated DICOM files were were combined into an 
image volume using the Teem (http://teem.sourceforge.
net/) software package. VHLab (SCANCO Medical) was 
used for segmenting out the vessels from the imaging 
data and used for volume measurements. SCIRun (SCI 
Institute) was used to generate 3D renderings as well as 
for calculating the total vascular surface area. SCANCO 
Medical’s software tools were used for evaluating 
vascular radius [36].
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tissue 
blocks from primary and metastatic clear cell RCC 
(ccRCC) were retrieved from Beth Israel Deaconess 
Medical Center under Dana Farber/ HCC IRB approved 
protocol 01-130. 12 primary ccRCCs were retrieved and 
one primary ccRCC was paired with a corresponding lung 
metastasis. Analysis was performed in selected areas of 
primary tumors containing low (G1-G2) and high (G3-G4) 
Fuhrman nuclear grade (FNG). Immunohistochemistry 
was performed on four micron-thick, FFPE tumor 
sections, which were initially deparaffinized, rehydrated 
and heated with a pressure cooker to 125°C for 30 seconds 
in citrate buffer for antigen retrieval and then incubated 
with peroxidase (Dako #S2003, Carpinteria, CA) and 
protein blocking reagents (Dako #X0909) respectively for 
5 minutes. Sections were then incubated with anti-BMP-9 
antibody (AbD Serotec #1406-1460) at 1:2000 dilution 
for 1 hour at room temperature followed by incubation 
with the Dako EnVision+ System HRP labeled polymer 
anti-rabbit (Dako #K4011) for 30 minutes. All sections 
were developed using the DAB chromogen kit (Dako 
K3468) for 2 minutes and then lightly counterstained with 
hematoxylin. The assay was validated using CHO cells 
that over express human BMP9 (generated at Acceleron 
Pharma, Inc.) and the parental CHO cell line. The 
presence of tumor cells with cytoplasmic staining was 
assessed. A case was considered positive if any positivity 
was detected. Immunohistochemistry of CD34 was 
performed on adjacent four-micron thick FFPE sections 
from sunitinib and ACE041, sunitinib only and vehicle 
treated xenografts as previously [37].
Transcriptome profiling using RNA 
quantification sequencing
Mice harboring A498 tumors were treated with 
vehicle (n=3), sunitinib (n=4), dalantercept (n=3) or a 
combination of sunitinib and dalantercept (n=4) and 
tumors were harvested for RNA preparation at 30 days or 
when tumors reached 20mm in long axis. Transcriptome 
profiles of the tumors were generated using next-
generation paired-end RNA sequencing.
Sequencing libraries were generated from double-
stranded cDNA using the Illumina TruSeq kit according 
to the manufacturer’s protocol for paired-end sequencing. 
Library quality was checked using the Agilent DNA High 
Sensitivity Chip and qRT-PCR. High quality libraries 
were sequenced on an Illumina HiSeq 2000. To achieve 
comprehensive coverage for each sample, we generated 
~35-50 million paired end reads.
RNA-Seq data analysis
The raw sequencing data was processed to remove 
adaptor, PCR primers and low quality transcripts using 
FASTQC and Trimomatic softwares. These high quality, 
clean reads were aligned against tumor (human, hg19) 
and host (mouse, mm10) genomes using tophat2 and 
bowtie2 software packages (http://tophat.cbcb.umd.edu/) 
[38]. Gene expression measurement was performed from 
aligned reads by counting the unique reads. The count 
data were preprocessed to remove all low expressing 
genes on the basis of counts per million (CPM) in 
samples (i.e. genes with CPM <1 in all samples). The 
read count based on gene expression data was normalized 
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on the basis of library complexity and gene expression 
variation. The normalized data was compared among 
groups using a negative binomial model to identify 
differentially expressed genes [39]. The differentially 
expressed genes were identified on the basis of multiple 
test corrected P values (i.e. FDR,5%) (27) and fold 
changes (±2). Comparative analysis of gene lists with 
external primary tumor angiogenesis signature [40] 
was performed through Venn diagrams. Unsupervised 
analysis was performed on normalized and preprocessed 
count data using Principal Component Analysis (PCA) 
[41]. For comparison of differentially expressed mouse 
and human genes, we performed orthologous gene 
identification analysis. We identified human orthologs 
of all differentially expressed mouse genes using NCBI 
homology database [42].
Pathway and regulatory molecules  
enrichment analysis
Ingenuity Pathway Analysis (IPA 8.0, Qiagen) was 
used to identify the pathways that are significantly affected 
by differentially expressed genes from different pairwise 
comparisons. The knowledge base of this software consists 
of functions, pathways and network models derived by 
systematically exploring the peer reviewed scientific 
literature. It calculates a p-value for each pathway 
according to the fit of users’ data to the IPA database using 
one-tailed Fisher exact test. The pathways with multiple 
test corrected p-values <0.01 were considered significantly 
affected.
The regulatory module analysis was used to 
identify the cascade of upstream transcriptional 
regulators in the treatment groups [43]. The significance 
of this analysis was determined using one-tailed Fisher 
exact test [44].
RT-PCR analysis
PCR primers were designed using the Primer 3 
software from NCBI [45] and synthesized by Integrated 
DNA Technologies. PCR was performed as described 
previously [46]. PCR reactions for each sample were 
performed in duplicate, and copy numbers were 
measured as described previously [47]. The level of 
target gene expression was normalized against 18S 
rRNA. For some genes instead of absolute expression 
estimation we have performed relative quantitation 
approach to determine the expression relative to 18S 
expression [48].
Statistical analysis
Statistical analysis of the data was done using 
GraphPad Prism 5 software (GraphPad Software Inc., 
La Jolla, CA) or Statistical functions developed using R 
language [49].
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